Sign in Subscribe
Apixaban

Atrial Fibrillation in Chronic Kidney Disease Patients May Benefit from Anticoagulant Therapy

Strategic Insights

— 1 min read

Patients with atrial fibrillation (AF) and chronic kidney disease (CKD) face significant challenges in managing their conditions due to the increased risk of thromboembolic and hemorrhagic complications. Research from Lazarski University in Warsaw, Poland, suggests that anticoagulant therapy may be beneficial for these patients, despite the potential risks. A systematic review of existing studies has revealed that anticoagulant therapy can maintain an adequate effect while reducing the risk of bleeding complications and renal function deterioration.

Key Takeaways:

  • Atrial fibrillation is a common arrhythmia in patients with chronic kidney disease (CKD), presenting a significant clinical challenge.
  • Anticoagulant therapy may be beneficial for patients with AF and CKD, particularly in advanced stages of CKD.
  • The use of anticoagulant therapy is associated with a lower risk of bleeding complications and renal function deterioration.
  • The main limitation of the analyzed studies is their observational nature, highlighting the need for further research in this area.
  • The systematic review presents the latest data on the safety and efficacy of anticoagulant therapy in patients with AF and CKD with a glomerular filtration rate of G4-G5.
  • The study emphasizes the importance of careful consideration and individualized treatment plans for patients with AF and CKD.
  • Janusz Bednarski and Katarzyna Anna Zlotorzynska are the authors of the study, which was published in the Medical Research Journal in 2025.
  • The study highlights the need for healthcare professionals to be aware of the risks and benefits of anticoagulant therapy in patients with AF and CKD.

Statistics:

  • The prevalence of atrial fibrillation in patients with chronic kidney disease is not specified in the study.
  • The glomerular filtration rate (GFR) of patients in the study ranged from G4-G5.
  • Anticoagulant therapy was associated with a lower risk of bleeding complications in patients with AF and CKD.
  • The use of anticoagulant therapy was also associated with a lower risk of renal function deterioration in patients with AF and CKD.

Sources:

  • Anticoagulant therapy in patients with atrial fibrillation and chronic kidney disease stage G4-G5 - systematic review. Medical Research Journal, 2025,10(3).
  • Via Medica, the publisher of the Medical Research Journal.
  • Doi: 10.5603/mrj.106259 (free access to the journal article)
  • Lazarski University, Department of Emergency and Disaster Medicine, Warsaw, Poland (Katarzyna Anna Zlotorzynska)
  • NewsRx. Studies from Lazarski University Yield New Data on Atrial Fibrillation (Anticoagulant therapy in patients with atrial fibrillation and chronic kidney disease stage G4-G5 - systematic review). Cardiovascular Week. October 20, 2025; p 2960.

Read more